Protara Beats Q2 Loss Estimates

Protara Therapeutics (NASDAQ:TARA) reported a narrower-than-expected GAAP net loss per share of $0.35 for Q2 2025, with revenue remaining at $0.0 million as the company is not yet commercial. The increased operational losses were attributed to higher R&D and administrative expenses, while the company continues to develop its lead asset, TARA-002, for bladder cancer and pediatric lymphatic malformations.

Want More Context? 🔎